Document is current

Article History

Received: 1 September 2023

Accepted: 20 November 2023

First Online: 13 December 2023

Declarations

:

: This study was approved by the Ethics Review Board in Stockholm, Sweden (2014/1287-31/4, 2018/972-32 and 2022-05774-02).

: Not applicable.

: All authors have completed the ICMJE uniform disclosure form at ExternalRef removed and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work. TGS has received research funding from Amgen and has received consulting fees from Aetion, for work unrelated to this manuscript. FE has served as advisory board member for Boehringer Ingelheim. HH reports research grants to his institution from Astra Zeneca, Pfizer, Merck, EchoSens, Intercept and Gilead, and board advisory for Bristol-Myers Squibb and Gilead. JS reports ownership in companies providing services to Itrim, Amgen, Janssen, Novo Nordisk, Eli Lilly, Boehringer, Bayer, Pfizer and AstraZeneca, outside the submitted work. JFL coordinates an unrelated study on behalf of the Swedish IBD quality register (SWIBREG), that has received funding from Janssen corporation. The remaining authors have no disclosures and no conflicts of interest to disclose.